Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
about
Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylationA health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigmStructural Basis of Substrate Recognition in Thiopurine S -Methyltransferase † ‡Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemiaEnhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogsIn vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profilePharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPsGenotyping panel for assessing response to cancer chemotherapy.Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.Systematic analysis of genotype-specific drug responses in cancer.Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Discovering tumor suppressor genes through genome-wide copy number analysis.Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphismSystematically characterizing and prioritizing chemosensitivity related gene based on Gene Ontology and protein interaction network.Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents.Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapyComparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome?Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.Genetic testing: predictive value of genotyping for diagnosis and management of disease.Compliance with a protocol for acute lymphoblastic leukemia in childhood.Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms.Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6)Pharmacogenomics in pediatric leukemia.Should pharmacogenomic studies be required for new drug approval?The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.A 50-year journey to cure childhood acute lymphoblastic leukemiaGermline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.Pharmacogenomics in bladder cancer.Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine.Perspectives on personalized cancer care.Pharmacogenomics of pediatric acute lymphoblastic leukemia.Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
P2860
Q24655104-5DDB8D8C-D081-4DA5-8989-3C64537C3278Q26866379-8DBE0F14-FC8E-4E2F-8F67-053D10623FFDQ27650629-E88D6BB3-69CD-4E42-845D-5CC3A69CE136Q28245060-08C3F4A8-2450-4A73-A3A4-6323B6DF6066Q28280315-E46D9250-C6E4-44BD-90CF-E06293813F5FQ28472573-A00A8EAD-A11A-4516-86F5-0DB56E60B932Q31144283-01CCA7AE-453A-4C28-AB25-1B457023B5A4Q33334373-80EFE763-3ED3-490E-93ED-9D69AE609F9FQ33343095-4529821E-4F47-4B8E-B95C-D1A94FED096FQ33395001-BDF8B22F-E90D-4486-A7B0-E2BDB5CEB7AAQ33395469-DC4A6EE6-22B7-452A-BA4B-76990B7B43C0Q33575305-B579D6C7-902E-4ED6-B9A0-3320FDB72501Q33576773-D8386CCB-1114-4818-97EC-AA95AA549128Q33751939-5CFB07DB-A7DC-44F7-B29D-CC07C65725A4Q33952766-3C6E14D1-272F-432E-8A5A-22BCEFA5A4D1Q34003323-B8685C8E-B95A-4ACA-976D-E61B3F288918Q34152841-1D6824A1-D4AC-4001-9B4A-A152A5AB7F16Q34429411-989ABD96-EBD8-4756-AB81-6249840DC19EQ34432563-ADC8C98C-5AFF-4D04-B620-A3C6F4A75812Q34483451-270DFBEA-AB96-4416-94FF-0A7978FCD1A4Q34549324-89C56622-DE3E-4F44-8B35-05B7727D849AQ34830088-42BEAB3A-DB1F-4F11-BE70-043CA6DC2301Q35135954-3BB8D544-934B-4AAA-A9B3-75880FAEA7B4Q35896845-735B5722-75F4-402A-BEAB-A7FFE768E597Q36117915-E020AF9D-8AD8-457A-8479-C8A7C6535BD0Q36153513-9D2B84B8-1C0A-431C-927B-DC3287F20502Q36224354-8CC6F379-1E8B-4476-90A0-44F9A87D5583Q36422106-F8016DB8-2AC4-4EA1-AA5E-F883743D81CCQ36571416-43486673-E2DA-4052-9564-1F9F032F2776Q36727952-FD03647B-B57F-48EC-8E15-DA3B6EE1D2F7Q36752667-AA311120-124E-45AE-BFC9-6FC351F54956Q37090821-AF339703-FBB5-4354-9951-B1729AC60307Q37166753-F85DB2BE-17A6-417B-8E47-CA79FED369C4Q37474395-4E74835D-CC0E-4868-A2CC-6A712ACADBAFQ37523551-9DCAEBF6-2AF3-4AA1-AA89-3EE72D482E49Q37724360-A5BC8635-6477-4D06-B573-C9A041B81420Q37730580-63BD131A-E501-41F2-89B0-0A0EE42653A5Q37739432-90F4E0C6-2139-4061-91AF-EFA5BF0CF4EBQ37808658-3BA034A9-E822-4B09-9F92-28C9BDFA160DQ38030053-F12F5E13-6E29-45D0-BC59-1B212AC12308
P2860
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@ast
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@en
type
label
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@ast
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@en
prefLabel
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@ast
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.
@en
P2860
P356
P1476
Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy
@en
P2093
William E Evans
P2860
P2888
P304
P356
10.1038/NRC1800
P407
P577
2006-02-01T00:00:00Z